

References

Chapter 34

- 1 Vrijens B, De Geest S, Hughes DA, Przemyslaw K, Demonceau J, Ruppap T, et al. A new taxonomy for describing and defining adherence to medications. *British Journal of Clinical Pharmacology*. 2012;**73**(5):691–705.
- 2 World Health Organization. Adherence to Long-Term Therapies: Evidence for Action. Available from: <http://apps.who.int/iris/bitstream/10665/42682/1/9241545992.pdf> (last accessed 18 November 2015).
- 3 Blaschke TF, Osterberg L, Vrijens B, Urquhart J. Adherence to medications: insights arising from studies on the unreliable link between prescribed and actual drug dosing histories. *Annual Review of Pharmacology & Toxicology*. 2012;**52**:275–301.
- 4 Vrijens B, Urquhart J, White D. Electronically monitored dosing histories can be used to develop a medication-taking habit and manage patient adherence. *Expert Reviews in Clinical Pharmacology*. 2014;**7**(5):633–44.
- 5 Pullar T, Kumar S, Tindall H, Feely M. Time to stop counting the tablets? *Clinical Pharmacology and Therapeutics*. 1989;**46**(2):163–8.
- 6 Podsadecki TJ, Vrijens BC, Tousset EP, Rode RA, Hanna GJ. ‘White coat compliance’ limits the reliability of therapeutic drug monitoring in HIV-1-infected patients. *HIV Clinical Trials*. 2008;**9**(4):238–46.
- 7 Patel M, Pilcher J, Travers J, Perrin K, Shaw D, Black P, et al. Use of metered-dose inhaler electronic monitoring in a real-world asthma randomized controlled trial. *Journal of Allergy and Clinical Immunology in Practice*. 2013;**1**(1):83–91.
- 8 Devonshire VA, Verdun di Cantogno E. Review of subcutaneous interferon beta-1a, delivered via the electronic self-injection device RebiSmart, for the treatment of multiple sclerosis. *Therapeutic Delivery*. 2011;**2**(11):1455–65.
- 9 Bruce JM, Hancock LM, Lynch SG. Objective adherence monitoring in multiple sclerosis: initial validation and association with self-report. *Multiple Sclerosis*. 2010;**16**(1):112–20.
- 10 Vrijens B, Tousset E, Rode R, Bertz R, Mayer S, Urquhart J. Successful projection of the time course of drug concentration in plasma during a 1-year period from electronically compiled dosing-time data used as input to individually parameterized pharmacokinetic models. *Journal of Clinical Pharmacology*. 2005;**45**(4):461–7.
- 11 Vrijens B, Urquhart J. Methods for measuring, enhancing, and accounting for medication adherence in clinical trials. *Clinical Pharmacology and Therapeutics*. 2014;**95**(6):617–26.
- 12 Demonceau J, Ruppap T, Kristanto P, Hughes DA, Fargher E, Kardas P, et al. Identification and assessment of adherence-enhancing interventions in studies assessing medication adherence through electronically compiled drug dosing histories: a systematic literature review and meta-analysis. *Drugs*. 2013;**73**(6):545–62.
- 13 Belknap R, Weis S, Brookens A, Au-Yeung KY, Moon G, Dicarolo L, et al. Feasibility of an ingestible sensor-based system for monitoring adherence to tuberculosis therapy. *PLoS ONE*. 2013;**8**(1):e53373.
- 14 Eisenberger U, Wuthrich RP, Bock A, Ambuhl P, Steiger J, Intondi A, et al. Medication adherence assessment: high accuracy of the new Ingestible Sensor System in kidney transplants. *Transplantation*. 2013;**96**(3):245–50.
- 15 US Food and Drug Administration. Guidance for Industry: Enrichment Strategies for Clinical Trials to Support Approval of Human Drugs and Biological Products. Available from: <http://www.fda.gov/downloads/Drugs/GuidanceCompliance>

- RegulatoryInformation/Guidances/UCM332181.pdf (last accessed 18 November 2015).
- 16** Osterberg LG, Urquhart J, Blaschke TF. Understanding forgiveness: minding and mining the gaps between pharmacokinetics and therapeutics. *Clinical Pharmacology and Therapeutics*. 2010;**88**(4):457–9.
- 17** Horne R, Weinman J, Hankins M. The beliefs about medicines questionnaire: the development and evaluation of a new method for assessing the cognitive representation of medication. *Psychology & Health*. 1999;**14**(1):1–24.
- 18** Michie S, Richardson M, Johnston M, Abraham C, Francis J, Hardeman W, et al. The behavior change technique taxonomy (v1) of 93 hierarchically clustered techniques: building an international consensus for the reporting of behavior change interventions. *Annals of Behavioral Medicine*. 2013;**46**(1):81–95.
- 19** de Bruin M, Viechtbauer W, Schaalma HP, Abraham C, Hospers HJ. Standard care impact on effects of highly active antiretroviral therapy adherence interventions. *Archives of Internal Medicine*. 2010;**170**(3):240–50.